Home / Biopharma (page 4)

Biopharma

Unusual Volume Rockers in Focus: Celgene Corporation (NASDAQ:CELG), UnitedHealth Group (NYSE:UNH)

Several matter pinch shares of Celgene Corporation (NASDAQ:CELG) [Trend Analysis], as shares plunging -2.28% to $117.24 with a share volume of 7.59 Million. Lets us look over what analysts have to say about performance of the CELG. Starting with EPS for the final quarter of this year. EPS is usually …

Read More »

Estimates Diverting Stocks’ Direction: Medtronic (NYSE:MDT), Keryx Biopharmaceuticals (NASDAQ:KERX)

Medtronic plc (NYSE:MDT) [Trend Analysis] knocking active thrust in leading trading session, shares a decrease of -0.61% to 74.44 with around 7.47 Million shares have changed hands in this session. Finally, analysts shed their light over the MDT price targets; maintaining price high target of 96 while at average the …

Read More »

Retaining Analysts Views in Focus: Horizon Pharmaplc (NASDAQ:HZNP), Aetna Inc. (NYSE:AET)

Horizon Pharmaplc (NASDAQ:HZNP) [Trend Analysis] plunged reacts as active mover, shares a loss -4.31% to trade at $17.31 and the percentage gap between open changing to regular change was 0.22%. Finally, analysts shed their light over the HZNP price targets; maintaining price high target of 42 while at average the …

Read More »

Stocks with Critical Profitability Analyses: Mast Therapeutics (NYSE:MSTX), Baxter International (NYSE:BAX)

Mast Therapeutics, Inc. (NYSE:MSTX) kept active in profitability ratio analysis, on current situation shares price jumping up -5.07% to $0.15. The total volume of 21.67 Million shares held in the session, while on average its shares change hands 9058.24 shares. Efficiency Evaluation in Focus Entering into profitability analysis, the co …

Read More »

Bristol-Myers Squibb (NYSE:BMY)- Making Way Towards North with Profitability Booster: Celsion (NASDAQ:CLSN)

Bristol-Myers Squibb Company (NYSE:BMY) also making a luring appeal, share price swings at $56.80 with percentage change of -5.30% in most recent trading session. Leerink analyst Seamus Fernandez wrote that the news “comes as an important surprise” and gives Merck “another leg up” in the race to develop cancer drugs. …

Read More »

Merck & Co. (NYSE:MRK)- Stocks having Bumpy Ride for the Day: Novartis AG (NYSE:NVS)

Drugmaker, Merck & Co., Inc. (NYSE:MRK) also run on active notice, stock price showed upbeat performance 2.85% after traded at $61.63 in most recent trading session.  Merck (MRK) could open itself up to the broader $12 billion-$14 billion lung-cancer market after the Food and Drug Administration accepted a supplemental filing …

Read More »

Valeant Pharmaceuticals International (NYSE:VRX)- Stocks Skyrockets on Unusual Volume: Amicus Therapeutics (NASDAQ:FOLD)

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) keeps its position active in context of investors’ investment valuation, price per shares crashed down -6.52% to $15.33 with volume of 28.51 Million.  Looking on other side, Forward Price to Earnings ratio of VRX persists on 2.92. Slightly noticeable ratio of firm is current ratio, …

Read More »

Hot Stocks Retreats on New Development: Sarepta Therapeutics, Inc. (NASDAQ:SRPT), Cempra, Inc. (NASDAQ:CEMP)

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) [Trend Analysis] swings enthusiastically in regular trading session, it an advance of 21.21% to close at $37.89. Finally to see some strong financial remarks by WSJ over SRPT performance. Out of the pool of analysts 11 gave their BUY ratings on the stock in …

Read More »

Reviving Stocks in Expert’s Opinion: Merrimack Pharmaceuticals (NASDAQ:MACK), PDL BioPharma (NASDAQ:PDLI)

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) [Trend Analysis] try to make new thrust in street and making different trends, stocks trading ended with -7.36% to $3.40. Fundamentalist can give brighter side of a picture but an analyst can glow the darker parts stored in any investment. Let us view how analysts have …

Read More »